Nuveen
STOK icon

Nuveen’s Stoke Therapeutics STOK Stock Holding History

Nuveen’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.02M Buy
122,877
+14,260
+13% +$458K ﹤0.01% 2211
2026
Q1 		$3.54M Buy
108,617
+4,356
+4% +$143K ﹤0.01% 2039
2025
Q4 		$3.31M Sell
104,261
-1,733
-2% -$52.1K ﹤0.01% 2090
2025
Q3 		$2.49M Buy
105,994
+3,526
+3% +$60.4K ﹤0.01% 2212
2025
Q2 		$1.16M Sell
102,468
-5,619
-5% -$53.4K ﹤0.01% 2534
2025
Q1 		$719K Hold
108,087
– – ﹤0.01% 2774
2024
Q4 		$1.19M Hold
108,087
– – ﹤0.01% 2636
2024
Q3 		$1.33M Sell
108,087
-79,264
-42% -$1.12M ﹤0.01% 2631
2024
Q2 		$2.53M Buy
187,351
+67,540
+56% +$912K ﹤0.01% 2270
2024
Q1 		$1.62M Buy
119,811
+56,480
+89% +$342K ﹤0.01% 2491
2023
Q4 		$333K Buy
63,331
+467
+0.7% +$2K ﹤0.01% 3126
2023
Q3 		$248K Sell
62,864
-763
-1% -$5.02K ﹤0.01% 2997
2023
Q2 		$676K Buy
63,627
+7,568
+14% +$80.5K ﹤0.01% 2830
2023
Q1 		$467K Sell
56,059
-6,525
-10% -$58.9K ﹤0.01% 2821
2022
Q4 		$578K Sell
62,584
-37,781
-38% -$393K ﹤0.01% 2848
2022
Q3 		$1.29M Buy
100,365
+26,329
+36% +$420K ﹤0.01% 2629
2022
Q2 		$978K Buy
74,036
+16,157
+28% +$245K ﹤0.01% 2788
2022
Q1 		$1.39M Buy
57,879
+722
+1% +$14.5K ﹤0.01% 2676
2021
Q4 		$1.02M Sell
57,157
-4,672
-8% -$111K ﹤0.01% 2856
2021
Q3 		$1.56M Sell
61,829
-30,621
-33% -$854K ﹤0.01% 2790
2021
Q2 		$3.11M Buy
92,450
+40,860
+79% +$1.44M ﹤0.01% 2493
2021
Q1 		$2M Buy
51,590
+480
+0.9% +$27.3K ﹤0.01% 2621
2020
Q4 		$3.17M Buy
51,110
+1,145
+2% +$52.5K ﹤0.01% 2284
2020
Q3 		$1.67M Sell
49,965
-6,183
-11% -$177K ﹤0.01% 2469
2020
Q2 		$1.34M Sell
56,148
-29,962
-35% -$711K ﹤0.01% 2497
2020
Q1 		$1.97M Buy
86,110
+64,698
+302% +$1.6M ﹤0.01% 2198
2019
Q4 		$606K Sell
21,412
-1,987
-8% -$50K ﹤0.01% 2860
2019
Q3 		$503K Buy
+23,399
New +$653K ﹤0.01% 2945

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen's STOK Position: Q2 2026 in Review

Nuveen increased its Stoke Therapeutics (STOK) stake by 13% in Q2 2026, buying an estimated $458K and bringing the position to 122,877 shares worth $4.02M. The position accounts for ﹤0.01% of the portfolio, ranked #2211.

Nuveen first reported a position in STOK in Q3 2019 and has held it in 28 quarters since. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Nuveen held 122,877 shares of Stoke Therapeutics worth $4.02M as of Q2 2026.
  • Nuveen bought 14,260 Stoke Therapeutics shares in Q2 2026, an estimated $458K.
  • Stoke Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2211 holding.
  • Nuveen first reported a position in Stoke Therapeutics in Q3 2019 and has held it in 28 quarters since.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.